CliffBio
small molecule

VIIBRYD

VILAZODONE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIIBRYD
Active ingredientVILAZODONE HYDROCHLORIDE
Strength20MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2011
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VIIBRYD patent cliff — loss of exclusivity — | CliffBio